Last reviewed · How we verify
NCT05134948: RELATIVITY 059
A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors
Phase 1, PHASE2 trial testing BMS-986213 in Advanced Solid Tumors in 24 participants. Completed in 24 October 2025.
1 September 2025
Quick facts
| Lead sponsor | Bristol-Myers Squibb |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 30 November 2021 |
| Primary completion | 1 September 2025 |
| Estimated completion | 24 October 2025 |
| Sites | 2 locations across China |
Drugs / interventions tested
- BMS-986213 — full drug profile →
Conditions studied
- Advanced Solid Tumors — all drugs for Advanced Solid Tumors →
Sponsor
Bristol-Myers Squibb — full company profile →
Who can join
18 and older, any sex, with Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to assess the safety, drug levels, immunogenicity and preliminary efficacy of BMS-986213 (nivolumab-relatlimab fixed-dose combination) in Chinese participants with advanced solid tumors.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application.
Huo JL, Wang YT, Fu WJ, Lu N, et al · · 2022 · cited 124× · PMID 35958563 · DOI 10.3389/fimmu.2022.956090 -
The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition.
Kreidieh FY, Tawbi HA. · · 2023 · cited 52× · PMID 37484526 · DOI 10.1177/17588359231186027 -
Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors.
Ghaedrahmati F, Esmaeil N, Abbaspour M. · · 2023 · cited 39× · PMID 36585761 · DOI 10.1002/cac2.12394 -
Deciphering T-cell exhaustion in the tumor microenvironment: paving the way for innovative solid tumor therapies.
Nair R, Somasundaram V, Kuriakose A, Krishn SR, et al · · 2025 · cited 28× · PMID 40236693 · DOI 10.3389/fimmu.2025.1548234 -
Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting.
Crimini E, Boscolo Bielo L, Berton Giachetti PPM, Pellizzari G, et al · · 2024 · cited 5× · PMID 38254772 · DOI 10.3390/cancers16020281 -
Overview of glutamine metabolism in stromal components of the tumor microenvironment and potential anti-tumor therapies.
Li Z, Deng J, Wang H, Liu T, et al · · 2026 · PMID 41659204 · DOI 10.1016/j.gendis.2025.101834
Verify or expand the search:
- PubMed search for NCT05134948
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of BMS-986213
Trials testing the same drug.
- NCT03662659 — An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Ju · Phase 2 · completed
- NCT01968109 — An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and With · Phase 1, PHASE2 · completed
Other recruiting trials for Advanced Solid Tumors
Currently open trials in the same condition.
- NCT07504445 — Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors · EARLY_PHASE1 · recruiting
- NCT07589530 — Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07360314 — Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors · Phase 1 · recruiting
- NCT07414316 — A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors. · EARLY_PHASE1 · recruiting
- NCT07222969 — A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Other Bristol-Myers Squibb trials
Trials by the same sponsor.
- NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
- NCT07459543 — A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unre · Phase 4 · not yet recruiting
- NCT07285798 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder · Phase 3 · not yet recruiting
- NCT07284745 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism · Phase 3 · not yet recruiting
- NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05134948 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bristol-Myers Squibb
- Last refreshed: 3 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05134948.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing